Home » Health & Medicine, Pharmaceuticals & Biotech, World » Diabetes Mellitus Therapeutics Market to Reach USD 10.2 Billion in Asia Pacific By 2021 – MarketIntelReports
“Type 2 Diabetes Mellitus Therapeutics Market in Asia-Pacific: Rise in the population with signs of diabetes through 2021.”
Type 2 Diabetes Mellitus Therapeutics Market in Asia-Pacific: Capital expenditure for R&D and production of drug for diabetes treatment

Diabetes mellitus is a group of metabolic diseases characterized by chronic hyperglycemia – high blood glucose levels – that result from defects in insulin secretion, insulin action, or a combination of these. This chronic hyperglycemia is associated with long-term damage, dysfunction, and failure of multiple organs including the eyes, kidneys, nerves, heart and blood vessels. Thus, the Type 2 Diabetes Mellitus Therapeutics Market has high scope for R&D through 2021.

Current trends of the Type 2 Diabetes Mellitus Therapeutics Market:

Empagliflozin (Jardiance, Lilly/Boehringer Ingelheim) lowered CV mortality by a significant 38%. It was shown to be renoprotective and significantly reduced the incidence of worsening nephropathy, by 39%.

Panacea Biotec has launched high-quality anti-diabetic drug called TENEPAN for the treatment of Type 2 diabetes Mellitus (T2DM) in the Type 2 Diabetes Mellitus Therapeutics Market.

In Bengaluru, India, Council for Scientific and Industrial Research (CSIR) has launched an ayurvedic drug called BGR-34. BGR-34 is an anti-diabetic ayurvedic drug designed for diabetes mellitus type 2 patients. It is economically priced at INR 5 for each tablet in Type 2 Diabetes Mellitus Therapeutics Market.

Complete research on Type 2 Diabetes Mellitus Therapeutics Market available at http://www.marketintelreports.com/report/gbihc380mr/type-2-diabetes-mellitus-therapeutics-in-asiapacific-markets-to-2021–increasing-usage-of-newer-therapies-and-expanding-treatment-population-to-encourage-robust-growth

Scope of the Type 2 Diabetes Mellitus Therapeutics in Asia Pacific Market:

The vast majority of diabetes mellitus patients can be classified as having either Type 1 Diabetes Mellitus (T1DM) or Type 2 Diabetes Mellitus (T2DM). Approximately 85-95% of all diabetics have T2DM in the Type 2 Diabetes Mellitus Therapeutics Market.

The current Type 2 Diabetes Mellitus Therapeutics Market in the Asia-Pacific (APAC) contains novel products, including Jardiance – a SGLT-2 inhibitor; Victoza – a GLP-1 receptor agonist; and Galvus – a DPP-4 inhibitor.

Analysis of clinical trials in the Type 2 Diabetes Mellitus Therapeutics Market, since 2006, identified that the failure rates of T2DM molecules were highest in Phase II, at 54%, with the overall attrition rate for T2DM at 82.6%.

Over the 2014-2021 forecast period, the Type 2 Diabetes Mellitus Therapeutics Market in the APAC market is expected to increase in value at a CAGR of 7.7%, from $6.07 billion to over $10.2 billion.

Order a copy of Type 2 Diabetes Mellitus Therapeutics Market report @ http://www.marketintelreports.com/purchase.php?id=gbihc380mr

Segmentation and key players of the Type 2 Diabetes Mellitus Therapeutics in Asia Pacific Market:

The Type 2 Diabetes Mellitus Therapeutics Market is segmented into various categories by treatment, by marketed drugs, by pipeline, by clinical trials, by promising pipeline molecules, by geography.

By treatment: Non-insulin T2DM Therapies, Insulin T2DM Therapies, Noninsulin Therapies and Insulin Therapies

By marketed drugs: Biguanides (Metformin), Sulfonylureas, Thiazolidinediones (Pioglitazone), GLP-1 receptor agonists (Byetta (exenatide), Bydureon (exenatide), Victoza (liraglutide), Lyxumia (lixisenatide), Tanzeum (albiglutide) and Trulicity (dulaglutide)), DPP-4 Inhibitors (Januvia/Glactiv (sitagliptin), Galvus (vildagliptin), Onglyza (saxagliptin), Trazenta (linagliptin), Zafatek (trelagliptin succinate) and Marizev (omarigliptin)), SGLT-2 Inhibitors (Forxiga (dapagliflozin), Invokana (canagliflozin) and Jardiance (empagliflozin)) and Insulin Therapies (Lantus (insulin glargine), Levemir (insulin detemir), Tresiba (insulin degludec) and Toujeo/ Lantus XR (insulin glargine))

By pipeline: pipeline distribution by stage of development, molecule type and program type, pipeline distribution by molecular target

By clinical trials: clinical trial failure rates, clinical trial duration, clinical trial size and clinical trial metrics analysis

By promising pipeline molecules: NN-9535 (subcutaneous semaglutide) and OG-217SC (oral semaglutide) – Novo Nordisk, ITCA 650 – Intarcia Therapeutics, Ertugliflozin – Pfizer

By geography: geographical markets, Asia Pacific Markets (China, India, Japan and Australia)

The key players in the Type 2 Diabetes Mellitus Therapeutics Market are as follows:

  • AstraZeneca
  • Merck & Co.
  • AbbVie
  • Janssen
  • Intarcia Therapeutics

The Type 2 Diabetes Mellitus Therapeutics in Asia-Pacific Market is a rapidly growing market with high potential in Asia Pacific as well as in the global market. High investment in R&D and drug production is made by any companies and pharmaceuticals across the globe. It is expected to witness high growth through 2021.

Check research sample here http://www.marketintelreports.com/pdfdownload.php?id=gbihc380mr

On a related note, another research on

Type 2 Diabetes Mellitus Therapeutics in Major Developed Markets to 2021- Strong Pipeline and Expanding Treatment Population to Encourage Robust Growth @ http://www.marketintelreports.com/report/gbihc366mr/type-2-diabetes-mellitus-therapeutics-in-major-developed-markets-to-2021–strong-pipeline-and-expanding-treatment-population-to-encourage-robust-growth

Type 1 Diabetes Mellitus Therapeutics in Major Developed Markets to 2021 – Innovative and Diversified Pipeline to Drive Market Growth Despite Patent Expirations @ http://www.marketintelreports.com/report/gbihc372mr/type-1-diabetes-mellitus-therapeutics-in-major-developed-markets-to-2021–innovative-and-diversified-pipeline-to-drive-market-growth-despite-patent-expirations

About Us:

MarketIntelReports (MIR) aim to empower our clients to successfully manage and outperform in their business decisions, we do this by providing Premium Market Intelligence, Strategic Insights and Databases from a range of Global Publishers.

MarketIntelReports currently has more than 10,000 plus titles and 35+ publishers on our platform and growing consistently to fill the “Global Intelligence Demand – Supply Gap”. We cover more than 15 industry verticals being: Automotive, Electronics, Manufacturing, Pharmaceuticals, Healthcare, Chemicals, Building & Construction, Agriculture, Food & Beverages, Banking & Finance, Media and Government, Public Sector Studies.

Media Contact
Company Name: MarketIntelReports
Contact Person: Mayur S.
Email: sales@marketintelreports.com
Phone: 1-302-261-5343
Address:2711 Centerville Road, Suite 400
City: Wilmington
State: Delaware
Country: United States
Website: www.marketintelreports.com

Comments are closed.